Pay in 4 interest-free payments of $5.34 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
We continue to champion collaboration between scientists and clinicians, always keeping patients at the center
Super fast shipping, great packaging and product
Which brings the story to the FDA vote
The discovery of BRAF mutations catalyzed the development of targeted therapies, significantly improving patient outcomes ( Figure 2 The approval of the BRAF inhibitor vemurafenib marked a significant advancement in the treatment of metastatic melanoma harboring BRAF V600 mutations ( In addition to their use in metastatic melanoma, BRAF and MEK inhibitors have also been explored in the adjuvant setting
US$ 27.61
US$ 27.14
US$ 26.80
